Triple-negative breast cancer (TNBC) accounts for 90 % of the basal-like type and is characterized by its biological aggressiveness, worse prognosis, and lack of therapeutic target in contrast with hormone receptor-positive and HER2-positive breast cancer [2, 3]. Here, ERBB2 is linked to breast cancer.